Physician profile
Thomas J King
NPI 1063453116
$3,443.89
in general payments reported to CMS, 2019-2025
40 companies · $992 in 2025
The $992 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $46.94 · 2022: $411 · 2023: $858 · 2024: $1,008 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.25 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $336.45 | 2023-2025 | |
| Novo Nordisk INC | $276.74 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $191.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $187.01 | 2022-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $182.13 | 2022-2025 | Veozah |
| Abbott Laboratories | $179.92 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $176.90 | 2023-2025 | |
| Glaxosmithkline, LLC. | $156.83 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $128.69 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $120.30 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $108.93 | 2024-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $94.20 | 2019-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $90.24 | 2022-2024 | |
| Heartflow, INC. | $87.25 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.